Evidence map›Paper›PMID 41651792›Full record

ArticleEuropean journal of haematology2026

Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.

Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03575351 (A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03575351 phase3completednot on this map

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

TypeinterventionalSponsorCelgeneRan2018 to 2023Enrolled184ConditionsLymphoma, Non-HodgkinArmsStandard of Care, JCAR017
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine ThieblemontHôpital Saint Louis, Service d'hématologie-Oncologie, Université de Paris Assistance Publique Des Hôpitaux de Paris (APHP), Paris, France.ORCID https://orcid.org/0000-0002-7109-6949
Florian ColratBristol Myers Squibb, Health Economics and Outcomes Research Department, Rueil-Malmaison, France.ORCID https://orcid.org/0009-0002-5985-0643
Rahma SellamiPutnam, HTA Operations Department, Paris, France.
Marine SivignonPutnam, HTA Operations Department, Paris, France.ORCID https://orcid.org/0000-0002-5399-127X
Adrien PetelBristol Myers Squibb, Medial Affairs Department, Rueil-Malmaison, France.
Sébastien BranchouxBristol Myers Squibb, Health Economics and Outcomes Research Department, Rueil-Malmaison, France.ORCID https://orcid.org/0000-0002-2728-9778
Gérard de PouvourvilleESSEC Business School, Cergy, France.ORCID https://orcid.org/0000-0002-5941-6823

Funding

Bristol Myers Squibb
6 · The paper itself

Abstract

objectivesCAR-T cell therapies such as lisocabtagene maraleucel (liso-cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B-cell lymphoma (LBCL). The objective of this study was to assess the cost-effectiveness of liso-cel compared to standard of care (SOC) to treat R/R LBCL in France.

methodsA 3-health-state model was developed to compare liso-cel to SOC over 20 years in France. Efficacy and safety were extrapolated from the TRANSFORM trial (NCT03575351), or DESCAR-T (registry of patients treated with a CAR-T in France). Costs were calculated using French-specific sources. Outcomes were quality-adjusted life years (QALY), life-years (LY), total costs, incremental cost-utility and cost-effectiveness ratios (ICUR, ICER). Probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results.

resultsLiso-cel generated 5.7 QALY (6.4 LY) for a €265 907. SOC generated 4.4 QALY (5.1 LY) for €233 903. ICUR and ICER were estimated at €24 580/QALY and €23 464/LY gained versus SOC. PSA showed that liso-cel was more effective and more costly in 92% of the simulations.

conclusionsLiso-cel is cost-effective versus SOC to treat R/R LBCL patients in France. Generation of long-term real-world data is needed in order to validate these findings.

Indexed as

Cost-Benefit AnalysisCost-Effectiveness AnalysisImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseClinical Trials, Phase III as TopicFranceHumansQuality-Adjusted Life YearsRandomized Controlled Trials as TopicReceptors, Chimeric AntigenRecurrenceRegistriesTreatment OutcomeReceptors, Chimeric AntigenCAR‐Tcost‐effectiveness analysisLBCLlisocabtagene maraleucel

Identifiers

PMID41651792
PMCPMC13141658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.